HISTORY
Our success story
It all started in 2008 with the first spin-off of the Department of Pharmacy at the Ludwig Maximilian University Munich (LMU) more than 15 years ago.
2023
KKR invests in Coriolis Pharma and the strategic growth partnership with Frontier Biosolutions. Coriolis gains access to KKR’s and Frontier Biosolutions’ global healthcare network to expand its’ global activities and growth plans focused on innovative, high-quality formulation research and development services.
Along with this, Dr. Michael Wiggenhorn, one of the founders of Coriolis, is joining the newly formed board of directors, together with Kugan Sathiyanandarajah, Partner at KKR and Head of the Health Care Strategic Growth business in Europe, as well as Nico Haller, Director of Health Care Strategic Growth.
Thomas Eldered, Executive Chairman of Flerie Invest and founder of Recipharm serves as Executive Chairman of Frontier Biosolutions.
2022
Coriolis opens a new facility for the formulation development of ATMPs, cell culture activities, particle characterization and identification, analytical ultracentrifugation and lyophilization development for gene and cell therapy drug products unter biosafety level S2. With this expansion Coriolis meets the increasing demand for development and analytical services for ATMPs. The total floor space of Coriolis increases to 7,800 m2.
2022
Coriolis names Silvia Steyrer-Gruber as Chief Executive Officer. In her previous role as Managing Director Europe at Exeltis (part of the Insud Pharma Group), Silvia was responsible for the European branded pharmaceutical business of the family-owned Spanish Multinational Healthcare Group. Prior to that, Silvia served at Baxter, Kwizda Pharma and Serono in senior roles, and gained more than 25 years of experience in Biotech, Vaccine and Pharmaceutical companies.
Dr. Michael Wiggenhorn and Thomas Wiggenhorn, both founders of Coriolis step to the Board of Directors.
2017
Coriolis relocates to its new company headquarters in Martinsried near Munich.
With this move Coriolis is now equipped to serve its clients in a laboratory and office space spanning over 6,900 square meters, including S1 and S2 as well as GMP capacities.
2012
Coriolis receives GMP accreditation by the Government of Upper Bavaria. Since then, Coriolis has been offering various services not only under R&D conditions but also under GMP conditions.
Every year, Coriolis is audited by various clients. The range of GMP services, particularly for the late development stages, is constantly being expanded over the years.
2009
Coriolis moves with its first employees to its own facilities in the Innovation and Start-Up Center for Biotechnology (IZB) at the Biotech Campus in Martinsried near Munich, Germany.
2008
Coriolis Pharma is born. As a spin-off company of the department of pharmacy (Pharmaceutical Technology and Biopharmaceutics) Coriolis starts its activities at the High Tech Campus of the Ludwig-Maximilians University (LMU) Munich, Germany under the management of Dr. Michael and Thomas Wiggenhorn. Further founding members are Dr. Andrea Hawe and Dr. Frank Schaubhut. The team is supported by an Advisory Board consisting of Prof. Dr. Gerhard Winter and Prof. Dr. Wolfgang Frieß.
